Azelaic acid foam, 15% (BAY39-6251) + Vehicle foam
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Papulopustular Rosacea
Conditions
Papulopustular Rosacea
Trial Timeline
Sep 1, 2012 → Jan 1, 2014
NCT ID
NCT01555463About Azelaic acid foam, 15% (BAY39-6251) + Vehicle foam
Azelaic acid foam, 15% (BAY39-6251) + Vehicle foam is a phase 3 stage product being developed by Bayer for Papulopustular Rosacea. The current trial status is completed. This product is registered under clinical trial identifier NCT01555463. Target conditions include Papulopustular Rosacea.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01555463 | Phase 3 | Completed |
Competing Products
18 competing products in Papulopustular Rosacea